Compare Recursion Pharmaceuticals Inc (RXRX) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.06 (market cap $2.14B), while Invesco S&P 500 Low Volatility ETF trades at $71.94 (market cap $6.94B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 1,663,703). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| RXRX | SPLV | |
|---|---|---|
Market Cap | $2.14B | $6.94B |
Volume | 30,789,535 | 1,663,703 |
Sector | Health | — |
52-Week High | $6.79 | $77.97 |
52-Week Low | $2.84 | $70.30 |
Typical Hold Time | 22 Days | 123 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
SPLV trades at $71.99, up 1.08% with a bearish technical outlook from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 provide income support, while technical indicators show mixed signals with neutral oscillators.
Outlook remains cautious due to sector headwinds and unappealing growth-adjusted valuation. The fund's low-volatility focus offers defensive positioning amid market uncertainty, though continued underperformance relative to broader market indexes presents near-term challenges for total return investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
